GeNeuro’s €17.5 Million Private Placement

McDermott Will & Emery and Gantey advised GeNeuro on the deal.

GeNeuro, a Swiss company listed on the regulated market of Euronext Paris, completed its €17.5 million capital increase realized by way of an international private placement of new shares to qualified institutional investors.

GeNeuro is a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases.

Bryan, Garnier & Co Limited acted as Sole Book Runner on the private placement and a prospectus was approved on January 31, 2020 by the French Autorité des marchés financiers in relation to the listing of the newly issued shares.

McDermott Will & Emery acted for GeNeuro with a team led in Paris by partner David Revcolevschi (corporate/capital markets; Picture).

In Geneva, the law firm Gantey advised GeNeuro on the Swiss law aspects with partners Christophe Buchwalder and Natasa Markovic.

Involved fees earner: Christophe Buchwalder – Gantey; Natasa Markovic – Gantey; David Revcolevschi – McDermott Will & Emery;

Law Firms: Gantey; McDermott Will & Emery;

Clients: Geneuro SA;